- Home
- LICN vs ENTO Comparison
LICN vs ENTO Comparison
Compare LICN & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- ENTO
- Stock Information
- Founded
- LICN 2004
- ENTO 2014
- Country
- LICN China
- ENTO United States
- Employees
- LICN N/A
- ENTO N/A
- Industry
- LICN
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- ENTO Health Care
- Exchange
- LICN Nasdaq
- ENTO Nasdaq
- Market Cap
- LICN 2.1M
- ENTO 1.9M
- IPO Year
- LICN 2023
- ENTO 2016
- Fundamental
- Price
- LICN $4.92
- ENTO $0.43
- Analyst Decision
- LICN
- ENTO
- Analyst Count
- LICN 0
- ENTO 0
- Target Price
- LICN N/A
- ENTO N/A
- AVG Volume (30 Days)
- LICN 1.7M
- ENTO 3.1M
- Earning Date
- LICN 01-01-0001
- ENTO 05-15-2025
- Dividend Yield
- LICN N/A
- ENTO N/A
- EPS Growth
- LICN N/A
- ENTO N/A
- EPS
- LICN N/A
- ENTO N/A
- Revenue
- LICN $41,477,000.00
- ENTO N/A
- Revenue This Year
- LICN N/A
- ENTO N/A
- Revenue Next Year
- LICN N/A
- ENTO N/A
- P/E Ratio
- LICN N/A
- ENTO N/A
- Revenue Growth
- LICN 4.32
- ENTO N/A
- 52 Week Low
- LICN $2.60
- ENTO $0.19
- 52 Week High
- LICN $488.00
- ENTO $2.86
- Technical
- Relative Strength Index (RSI)
- LICN 49.93
- ENTO 55.80
- Support Level
- LICN $5.61
- ENTO $0.37
- Resistance Level
- LICN $6.16
- ENTO $0.68
- Average True Range (ATR)
- LICN 1.10
- ENTO 0.08
- MACD
- LICN -0.11
- ENTO 0.00
- Stochastic Oscillator
- LICN 40.85
- ENTO 25.15
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.